Proteomics and Metabolomics Shared Resource-Stephen Byers, PhD /Albert Fornace, Jr, MD The mission of the Proteomics and Metabolomics Shared Resource (PMSR) is to provide state-of-the-art tools, methods, and mass spectrometry-based technology to investigators. This centralized shared resource is available to researchers for routine and specialized proteomic and metabolomic applications.
The aim of PMSR is to provide an 'in house'resource, rich in technical expertise that fosters the free flow of experimental knowledge and collaborations across the Lombardi Comprehensive Cancer Center (Lombardi). The PMSR offers an array of proteomics- and metabolomics-based services. It is equipped with two-dimensional (2D) gel electrophoresis apparatus including DIGE imager and spot picker (GE Healthcare), 4800 MALDI TOF-TOF instrument (ABI), and a QSTAR Elite Hybrid LC MS/MS system (ABI) to support the proteomic workflow. Each instrument has the latest integrated software and database search engines (e.g.. Protein Pilot, GPS explorer) for protein identification and data processing. In addition, PMSR houses a QTOF Premier (Waters Corp.) online with an UPLC system for metabolomic profiling and drug metabolism studies. The data processing for metabolite biomarker studies is supported by the 'SIMCA-P'and the 'Random Forest software'. PMSR also manages a 4000 QTrap, which supports quantitation and validation for small-molecule metabolites, and allows targeted proteomic analysis. PMSR staff includes a dedicated bioinformatician who works closely with the Biostatistics and Bioinformatics Shared Resource (BBSR), as well as with the Georgetown University-based Protein Information Resource (PIR). The most common experiments include identification of proteins contained in bands/spots isolated from electrophoretic gels, as well as comparative proteomics using shotgun and stable isotope labeling strategies. The high speed, sensitivity, and accuracy of our mass spectrometry experiments allow accurate qualitative and quantitative proteomics. The metabolomics initiative has been driven by Dr. Albert Fornace, Jr, and involves UPLC-TOFMS based biomarker discovery for radiation exposure. This technology is now available to investigators for their specific research interests. Written and electronic reports are provided for all samples, and the average turn-around time is two weeks. The PMSR is able to carry out experiments that detect and characterize protein modifications such as phosphorylation and acetylafion. These experiments are challenging and require a more intensive effort. However, the combination of the complementary mass spectrometric methods available in PMSR, staff expertise and experience, and the ability to work closely with investigators, have allowed the successful completion of a number of these difficult projects. The PMSR was established in January 2006 and has grown dramatically, both in resources and use. Lombardi has invested over $1 million in equipment alone for the PMSR;as a result, the facility consistently provides high quality data to many investigators from 5 programs within Lombardi. The PMSR is run under the directorship of Drs. Stephen Byers and Albert Fornace Jr.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Rao, Guanhua; Pierobon, Mariaelena; Kim, In-Kyu et al. (2017) Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep 7:7066
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2017) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother :
Vietsch, Eveline E; Graham, Garrett T; McCutcheon, Justine N et al. (2017) Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet 218-219:39-50
Lynce, Filipa; Barac, Ana; Tan, Ming T et al. (2017) SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist 22:518-525
Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438
Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:
DeVito, Stephen; Woodrick, Jordan; Song, Linze et al. (2017) Mutagenic potential of hypoxanthine in live human cells. Mutat Res 803-805:9-16
Wang, Hongkun; Wang, Ying; Kota, Krishna K et al. (2017) Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder. Sci Rep 7:13493
Parodi, Daniela A; Greenfield, Morgan; Evans, Claire et al. (2017) Alteration of Mammary Gland Development and Gene Expression by In Utero Exposure to Cadmium. Int J Mol Sci 18:
Casero, David; Gill, Kirandeep; Sridharan, Vijayalakshmi et al. (2017) Space-type radiation induces multimodal responses in the mouse gut microbiome and metabolome. Microbiome 5:105

Showing the most recent 10 out of 997 publications